Exchange Commission on Thursday to consider a raft of reforms, after William Ackman's aggressive efforts to take over Allergan Inc raised concerns about loose rules governing disclosure and shareholder voting.
By Uncommon Profit Investor : Unlike Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ..... Valeant's June 17th call for this article. Allergan about to be rid of Valeant? Allergan 's CEO sounded far more confident in Allergan 's
Aren't Stocks Down More? Visa (NYSE: V ), MasterCard (NYSE: MA ), Valeant Pharmaceuticals (NYSE: VRX ), Allergan (NYSE: AGN ), Time Warner (NYSE: TWX ), Twenty-First Century Fox (NASDAQ: FOX ), International Game Technology
Allergan , Inc . (NYSE: AGN ) Q2 2014 Earnings Conference Call July 21, 2014, 10:30 AM ET ..... Finkelstein - Susquehanna Presentation Operator Hello, and welcome to the Allergan Second Quarter 2014 Earnings Call. Following today’s presentation
July 21 (Reuters) - Allergan Inc , which is fighting a hostile bid from Valeant Pharmaceuticals International Inc , said on Monday it would cut 13 percent of its workforce as part of a restructuring...
By Uncommon Profit Investor : This quote is from Warren Buffett's 2002 letter to Berkshire Hathaway (BRK.A (NYSE: BRK.B ) shareholders. It is important because Valeant Pharmaceutical's (NYSE: VRX ) "cash EPS" is nothing but "earnings before depreciation, amortization, restructuring, integration, ...
July 21 (Reuters) - Investor William Ackman, who owns nearly 10 percent of Botox maker Allergan Inc , said on Monday that the likelihood of Valeant Pharmaceuticals International Inc succeeding in its hostile takeover for Allergan increased on Monday.
July 21 (Reuters) - Allergan Inc : * CEO, in investor conference call, says interested in acquiring new types of businesses * CEO says could buy one or more new types of businesses that may become new
Allergan ’s strong growth this quarter combined ..... We wouldn’t be surprised to see Allergan attempt some form of a tax inversion ..... are still cautious of implications for Allergan ’s wide economic moat if a tax-incentivized
Allergan (NYSE: AGN ) Q2 results : Revenues: $1,864.2M (+16.7%), Specialty Pharmaceuticals: $1,526.1M (+13.2%), Medical Devices